CD14 and prostate carcinoma: Interestingly, Idorn et al., showed that the levels of CD14+HLA-DRlow/− M-MDSCs were increased in both untreated and docetaxel-treated CRPC patients and that they were correlated with a shorter median OS, suggesting that MDSCs support prostate cancer progression (191).